The good news is here, the House voted 296-121 Friday to pass a $915-billion spending package to fund the federal government for the rest of the fiscal year, likely staving off a threatened midnight government shutdown. Now we have to hear from the Senate to be sure that the Prostate Cancer Research Program in the [...]
I woke up this morning to some potentially good news. Last night the congressional committee finalized their reconciliation report and filed the final FY12 Omnibus Report. I am over joyed to report that the Report included the Peer Reviewed Compressional Directed Medical Research Programs that had become the target of budget cutters. Many of us [...]
Prostate cancer is more prevalent in higher latitudes. This has been correlated with Vitamin D metabolism and its effect on tissue differentiation. Autopsies have shown that incidental prostate cancer is noted in 30% of men in the 6th decade of life and increases significantly through the ninth decade. These data have been reproduced in populations [...]
One of the major causes of prostate cancer morbidity and mortality is bone metastases. Currently, when it comes to treating prostate cancer metastases we are very limited in effective therapies that actually prolong survival. Kirschenbaum A, etal (Departments of Urology and Medicine Division of Pulmonary Diseases Division of Endocrinology, Metabolism, and Bone Diseases, Mount Sinai [...]
The use of denosumab (Xgeva) as an alternative to the more commonly prescribed zoledronic acid (Zometa) to slow down the development of bone metastases in men with advanced prostate cancer is becoming more common. The most common concern for men taking Zometa and now Xgeva has been osteonecrosis of the jaw. Osteonecrosis of the jaw [...]